Logo image of SPNE

SEASPINE HOLDINGS CORP (SPNE) Stock Fundamental Analysis

USA - NASDAQ:SPNE - US81255T1088 - Common Stock

9.54 USD
+0.73 (+8.29%)
Last: 1/4/2023, 8:00:02 PM
9.35 USD
-0.19 (-1.99%)
After Hours: 1/4/2023, 8:00:02 PM
Fundamental Rating

2

Overall SPNE gets a fundamental rating of 2 out of 10. We evaluated SPNE against 191 industry peers in the Health Care Equipment & Supplies industry. SPNE may be in some trouble as it scores bad on both profitability and health. While showing a medium growth rate, SPNE is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year SPNE has reported negative net income.
SPNE had a negative operating cash flow in the past year.
SPNE Yearly Net Income VS EBIT VS OCF VS FCFSPNE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 -20M -40M -60M

1.2 Ratios

SPNE has negative profitability rations, so we won't be analyzing them here.
Industry RankSector Rank
ROA N/A
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
SPNE Yearly ROA, ROE, ROICSPNE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 -10 -20 -30

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for SPNE so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
SPNE Yearly Profit, Operating, Gross MarginsSPNE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 0 20 -20 40 -40 60

More info and screens

3

2. Health

2.1 Basic Checks

SPNE does not have a ROIC to compare to the WACC, probably because it is not profitable.
SPNE has more shares outstanding than it did 1 year ago.
SPNE has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
SPNE Yearly Shares OutstandingSPNE Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 10M 20M 30M
SPNE Yearly Total Debt VS Total AssetsSPNE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 100M 200M 300M

2.2 Solvency

Based on the Altman-Z score of 1.40, we must say that SPNE is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of SPNE (1.40) is comparable to the rest of the industry.
SPNE has a Debt/Equity ratio of 0.09. This is a healthy value indicating a solid balance between debt and equity.
SPNE has a Debt to Equity ratio (0.09) which is in line with its industry peers.
Industry RankSector Rank
Debt/Equity 0.09
Debt/FCF N/A
Altman-Z 1.4
ROIC/WACCN/A
WACC8.68%
SPNE Yearly LT Debt VS Equity VS FCFSPNE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 0 100M 200M 300M

2.3 Liquidity

SPNE has a Current Ratio of 3.18. This indicates that SPNE is financially healthy and has no problem in meeting its short term obligations.
SPNE has a Current ratio of 3.18. This is comparable to the rest of the industry: SPNE outperforms 44.95% of its industry peers.
A Quick Ratio of 1.65 indicates that SPNE should not have too much problems paying its short term obligations.
SPNE's Quick ratio of 1.65 is on the low side compared to the rest of the industry. SPNE is outperformed by 67.89% of its industry peers.
Industry RankSector Rank
Current Ratio 3.18
Quick Ratio 1.65
SPNE Yearly Current Assets VS Current LiabilitesSPNE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 50M 100M 150M

More info and screens

5

3. Growth

3.1 Past

SPNE shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -20.41%.
The Revenue has grown by 26.03% in the past year. This is a very strong growth!
SPNE shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 8.23% yearly.
EPS 1Y (TTM)-20.41%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%12.5%
Revenue 1Y (TTM)26.03%
Revenue growth 3Y10.11%
Revenue growth 5Y8.23%
Sales Q2Q%44.57%

3.2 Future

The Earnings Per Share is expected to grow by 2.06% on average over the next years.
Based on estimates for the next years, SPNE will show a quite strong growth in Revenue. The Revenue will grow by 11.60% on average per year.
EPS Next Y-1.82%
EPS Next 2Y8.56%
EPS Next 3Y11.83%
EPS Next 5Y2.06%
Revenue Next Year24.57%
Revenue Next 2Y17.4%
Revenue Next 3Y16.89%
Revenue Next 5Y11.6%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
SPNE Yearly Revenue VS EstimatesSPNE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 100M 200M 300M
SPNE Yearly EPS VS EstimatesSPNE Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 -1 -2 -3

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

SPNE reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for SPNE. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SPNE Price Earnings VS Forward Price EarningsSPNE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SPNE Per share dataSPNE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 6

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y8.56%
EPS Next 3Y11.83%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for SPNE!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

SEASPINE HOLDINGS CORP

NASDAQ:SPNE (1/4/2023, 8:00:02 PM)

After market: 9.35 -0.19 (-1.99%)

9.54

+0.73 (+8.29%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)11-01 2022-11-01/amc
Earnings (Next)03-09 2023-03-09
Inst OwnersN/A
Inst Owner ChangeN/A
Ins Owners6.42%
Ins Owner Change0%
Market Cap354.91M
Analysts85.71
Price Target16.13 (69.08%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-20.48%
Min EPS beat(2)-35%
Max EPS beat(2)-5.95%
EPS beat(4)0
Avg EPS beat(4)-27.95%
Min EPS beat(4)-47.45%
Max EPS beat(4)-5.95%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)0.92%
Min Revenue beat(2)0.23%
Max Revenue beat(2)1.61%
Revenue beat(4)3
Avg Revenue beat(4)0.68%
Min Revenue beat(4)-0.65%
Max Revenue beat(4)1.61%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)N/A
EPS NQ rev (1m)0%
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)N/A
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.54
P/FCF N/A
P/OCF N/A
P/B 1.29
P/tB 2.31
EV/EBITDA N/A
EPS(TTM)-1.77
EYN/A
EPS(NY)-1.33
Fwd EYN/A
FCF(TTM)-2.16
FCFYN/A
OCF(TTM)-1.22
OCFYN/A
SpS6.18
BVpS7.38
TBVpS4.12
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA N/A
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.61
Health
Industry RankSector Rank
Debt/Equity 0.09
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 212.78%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.18
Quick Ratio 1.65
Altman-Z 1.4
F-Score3
WACC8.68%
ROIC/WACCN/A
Cap/Depr(3y)159.81%
Cap/Depr(5y)125.57%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-20.41%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%12.5%
EPS Next Y-1.82%
EPS Next 2Y8.56%
EPS Next 3Y11.83%
EPS Next 5Y2.06%
Revenue 1Y (TTM)26.03%
Revenue growth 3Y10.11%
Revenue growth 5Y8.23%
Sales Q2Q%44.57%
Revenue Next Year24.57%
Revenue Next 2Y17.4%
Revenue Next 3Y16.89%
Revenue Next 5Y11.6%
EBIT growth 1Y-27.4%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year71.08%
EBIT Next 3Y25.82%
EBIT Next 5Y14.6%
FCF growth 1Y-150.58%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-136.29%
OCF growth 3YN/A
OCF growth 5YN/A